Publication | Closed Access

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

CytokineMedicineT-regulatory CellImmunologyHematologyPathologyIl-6 Plasma LevelsImmune SurveillanceEarly Molecular ResponseCml PatientsImmune Dysregulation